

Off-the-shelf iPSC derived CAR-NK immunotherapy for solid tumors
Principal Scientist Dr Nicholas Boyd
The clinical impact of Chimeric Antigen Receptor T cell (CAR-T) technologies on hematological malignancies have revolutionized cancer treatment.
However, current autologous CAR-T therapies face major roadblocks for mass adoption.
Despite progress in developing cell therapies, such as T cell or stemcell therapies to treat diseases, immunoincompatibility remains a major barrier to clinical application.
Given the fact that a host’s immune system may reject allogeneic transplanted cells, methods have been developed to genetically modify patients’primary cells.
In October 2019 Cartherics attended the prestigious Cell & Gene Meeting on the Mesa https://www.meetingonthemesa.com/ in Carlsbad, California.
Cartherics Chief Scientific Officer, Richard Boyd, presented details to delegates of Cartherics’ pre-clinical in vitro and animal model research, cell manufacture for clinical trials, and corporate game plan.